Generic cancer drug shows promise in small bioequivalence study

NCT ID NCT03050177

Completed Knowledge-focused Sponsor: Hunan Kelun Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a generic gefitinib tablet (made by Hunan Kelun) works the same as the brand-name drug Iressa in 38 healthy Chinese men. Each participant took a single dose of either the generic or brand-name drug after a meal, then switched to the other. Researchers measured drug levels in the blood to compare how the body absorbs and processes each version. The goal was to see if the generic is a suitable alternative for treating certain cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gefitinib tablet (generic vs. brand-name Iressa)
What this could lead to: If successful, this could show that the generic gefitinib is a safe and effective alternative to the brand-name drug, potentially lowering treatment costs.
What could go wrong: This is a small, early-phase study in healthy volunteers, not patients. Results may not predict how the drug works in people with cancer or under different conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

More trials for these conditions

Other studies related to the condition(s) this trial covers.